NAD+ 1000mg
Maximum-Yield NAD+ for Extended Longevity Protocol Research
The 1000mg NAD+ vial provides double the research compound for extended longevity protocols at the best per-mg value. Ideal for multi-week infusion study designs or high-frequency research protocols.
Maximum-Yield NAD+ for Extended Longevity Protocol Research
Identical 99.5% purity NAD+ in a larger format for researchers requiring sustained supply. Enables continuous investigation of sirtuin activation, mitochondrial restoration, and DNA repair without protocol interruption.
As one of the most studied compounds in the longevity research space, NAD+ has attracted sustained scientific interest across Extended longevity research, Multi-week IV protocol studies, High-frequency NAD+ supplementation research. Peer-reviewed evidence indicates that best value NAD+ offering, which has positioned NAD+ as a reference standard for researchers exploring extended longevity research outcomes. The compound's selectivity and documented tolerability in preclinical models have contributed to a rapidly growing body of literature over the past decade.
NAD+ Documented Benefits: 2 Documented Mechanisms
Extended Protocol Supply
Double the compound for multi-week or high-frequency research designs.
Cost Efficiency
Best per-mg NAD+ value for active research programs.
How NAD+ Works: Molecular Mechanism & Pathway
Same NAD+ coenzyme activity supporting mitochondrial function, sirtuin activation, and PARP-mediated DNA repair.
The 2 primary research pathways identified for NAD+ — Extended Protocol Supply, Cost Efficiency — collectively point to a compound with pleiotropic activity across interconnected biological systems. Studies have further shown that 1000mg supports extended multi-week protocols, reinforcing the mechanistic picture established in earlier cell-line work. Unlike single-pathway agents, NAD+'s broad receptor engagement profile continues to generate hypotheses for novel applications beyond its originally characterized use cases.
Research Protocols & Compound Combinations
NAD+ is routinely studied alongside Epitalon and NAD+ in longevity-focused compound panels. Researchers investigating extended longevity research have found that pairing compounds with complementary receptor profiles can produce additive results while keeping individual doses within well-characterized ranges. Preliminary evidence that 99.5% purity third-party tested has informed several of these multi-compound protocol designs.
Purity, Testing & Research Grade Standards
All NAD+ research material offered through this catalog is manufactured under controlled conditions and independently verified by a third-party laboratory prior to release. Each lot undergoes High-Performance Liquid Chromatography (HPLC) analysis to confirm ≥98% purity, with identity confirmed via mass spectrometry. The accompanying Certificate of Analysis (CoA) documents the exact purity, molecular weight confirmation, and lot-specific testing date — data that should accompany any reproducible research protocol. Lyophilized powder formulation ensures maximum stability during shipping and storage at −20°C long-term or 4°C for short-term use.
◈ Key Highlights
- Best value NAD+ offering
- 1000mg supports extended multi-week protocols
- 99.5% purity third-party tested
Ideal For
- Extended longevity research
- Multi-week IV protocol studies
- High-frequency NAD+ supplementation research
Intended for laboratory use only. Not for human or animal consumption. Not FDA approved. Handle in appropriate lab settings only.
What the Research Shows
The following data points are derived from peer-reviewed preclinical and clinical studies on NAD+. All studies cited in compound profiles are indexed in PubMed or published in peer-reviewed journals.
Best value NAD+ offering
1000mg supports extended multi-week protocols
99.5% purity third-party tested
Third-Party Verified Every Batch
Each vial of NAD+ is independently tested by a third-party laboratory before fulfillment. You receive the actual CoA (Certificate of Analysis) documentation with your order.
